Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05644093
Other study ID # CT026_003
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 3, 2023
Est. completion date April 5, 2023

Study information

Verified date March 2024
Source Small Pharma Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test SPL026 given via injection into a muscle in healthy volunteers.


Description:

Part A: Crossover IM then IV dosing with SPL026 in psychedelic experienced, healthy volunteers. PART B: IM dosing only with SPL026 in less experienced/psychedelic naive, healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date April 5, 2023
Est. primary completion date April 5, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: Part A only 1. Healthy psychedelic-experienced female or male participants (psychedelic-experienced is defined as having at least 2 previous experiences, with breakthrough, of serotonergic psychedelic drugs, including but not limited to: DMT, ayahausca, LSD, LSA [morning glory seeds], DOI [2,5-Dimethoxy-4- iodoamphetamine], DOB [dimethoxybromoamphetamine], DOC [2,5- Dimethoxy-4-chloroamphetamine], 2CB [2-(4-bromo-2,5- dimethoxyphenyl)ethanamine], 2CE [1-(2,5-Dimethoxy-4-ethylphenyl)-2- aminoethane], mescaline, peyote, san pedro, ibogaine and psilocybin [including mushroom species containing psilocybin]). 2. No psychedelic drug use within 6 weeks prior to dosing. Part B only 3. Healthy female or male participants with little to no psychedelic experience (defined as having never taken serotonergic psychedelic drugs, or have only taken sub-breakthrough doses of serotonergic psychedelic drugs, in any form, < 5 times, including but not limited to: DMT, ayahuasca, LSD, LSA, DOI, DOB, DOC, 2CB, 2CE, mescaline, peyote, san pedro, ibogaine and psilocybin [including mushroom species containing psilocybin]). 4. No psychedelic drug use within 6 months prior to dosing. Parts A and B 5. Aged 25-65 years. 6. A body mass index (BMI; Quetelet index) in the range 18.0-33.9 kg/m2. Body Mass Index = 7. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 8. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate. 9. Agree to follow the contraception requirements of the trial. 10. Agree not to donate blood or blood products during the study and for up to 3 months after the (last) administration of the trial medication. 11. Willing to refrain from psychedelic drug use (excluding the study drug) during the trial and until the follow up call. 12. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS). 13. Willing to be contacted by email and video call, and have online access. 14. Has veins deemed suitable for cannulation (IV infusion and/or blood sampling). Exclusion Criteria: 1. Current or previously diagnosed mental health disorder as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria. 2. First degree relative with schizophrenia spectrum or other psychotic disorders, or bipolar and related disorders. 3. Disposition judged by the investigator (or delegate) to be incompatible with establishment of rapport with therapy team and/or safe exposure to DMT. 4. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception (see section 11). 5. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the participant. 6. Presence of acute or chronic illness, condition or infection, or history of chronic illness or condition (including psychological and neurological [eg seizure] disorder) considered sufficient to invalidate the participant's participation in the trial or make it unnecessarily hazardous. 7. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or any of the following cardiovascular conditions: arrhythmia, a clinically significant screening ECG abnormality or family history of long QT syndrome or sudden death, artificial heart valve, current or any history of hypertension, or any other significant current or history of cardiovascular condition, that may affect safety in the opinion of the investigator. 8. History of serious suicide attempts (ie those that require hospitalisation); as assessed by the BSS. 9. Presence or history of severe adverse reaction to any drug or a history of sensitivity to serotonergic psychedelic drugs. 10. Use of a prescription medicine (except oral contraceptives or any hormone therapy), certain herbal supplements (eg St John's Wort, to be reviewed by trial physician), or over-the-counter medicine, during the 28 days before the first dose of trial medication. Use of acetaminophen (paracetamol) and non-steroidal anti-inflammatory drugs (eg ibuprofen) are permitted up to 4 h before the first dose of trial medication. 11. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before (first) admission to this study; in the follow-up period of another clinical trial at the time of screening for this study. 12. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly. 13. Daily cannabis use or cannabis dependence as defined by ICD10. 14. Use of cannabis in the 24 h before each study visit. 15. Evidence of drug abuse on urine testing (with the exception of cannabis). 16. Unable to be nicotine free (refrain from smoking or nicotine-containing products) for 24 h before and until the morning after dosing. 17. Blood pressure and pulse rate in the supine and standing position at the screening examination outside the ranges: blood pressure 80-150 mm Hg systolic; 30-100 mm Hg diastolic; pulse rate 40-100 beats/min. Borderline values (ie values that are within 5 mm Hg of the range for blood pressure or 5 beats/min of the range for pulse rate) will be repeated. Participants can be included if the repeat value is within range or still borderline but deemed not clinically significant by the investigator. 18. QTcF value at screening greater than 450 msec (men) or 470 msec (women) on 12-lead ECG. Triplicate measurements will be made, and a mean QTcF value higher than 450 msec (men) or 470 msec (women) will lead to exclusion. A repeat (in triplicate) is allowed on one occasion for determination of eligibility. 19. Possibility that the participant will not cooperate with the requirements of the protocol. 20. Positive test for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). 21. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor. 22. Phobia of needles or blood. 23. Objection by General Practitioner (GP) to participant entering trial.

Study Design


Intervention

Drug:
SPL026 IV
IV dosing
SPL026 IM
IM dosing

Locations

Country Name City State
United Kingdom Hammersmith Medicines Research London

Sponsors (1)

Lead Sponsor Collaborator
Small Pharma Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lab biochemistry [Safety & Tolerability] Values of potential clinical importance Change from baseline at Day 1 post dose
Primary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Adverse Events (AEs) Throughout the study until 14 days after dosing (Day 15 EOS)
Primary Heart Rate [Vital Signs - Safety & Tolerability] pulse rate will be measured in bpm Change from baseline heart rate at Day 1 or Day 2 post dose
Primary Blood Pressure [Vital Signs - Safety & Tolerability] arterial blood pressure Change from baseline blood pressure at Day 1 or Day 2 post dose
Primary Temperature [Vital Signs - Safety & Tolerability] tympanic temperature Change from baseline temperature at Day 1 or Day 2 post dose
Primary 12-lead ECG [Safety & Tolerability] QTcX intervals Change from baseline ECG at Day 1 or Day 2 post dose
Primary Physical Exam [Safety & Tolerability] Full physical exam screening and a brief symptom guided exam at Day -1 and Day 1 Change from baseline at Day 1 post dose
Primary Beck Scale for Suicidal Ideation (BSS) - [Safety & Tolerability] The Beck Suicidal Ideation scale to monitor suicidal ideation Change from baseline at Day 15 post dose
Secondary Evaluation of plasma levels of DMT Pharmacokinetic parameter calculation Day 1
Secondary Mystical Experience Questionnaire (MEQ) - [Pharmacodynamics - Psychometric Scales and Questionnaires] Compare MEQ between different routes of administration (IV & IM) Day 1 (dosing day)
Secondary Challenging Experience Questionnaire (CEQ) - [Pharmacodynamics - Psychometric Scales and Questionnaires] Compare CEQ between different routes of administration (IV & IM) Day 1 (dosing day)
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A